Boehringer Ingelheim Spiriva Respimat for asthma

RIDGEFIELD, Conn. — Boerhringer Ingelheim Pharmaceuticals on Wednesday announced that its Spiriva (tiotropium bromide) Respimat was available for patients by prescription as an asthma maintenance medication in patients older than 12 years of age. 

 

The steroid-free bronchodilator had previously been approved for treatment of chronic obstructive pulmonary disease (COPD), but was recently approved for asthma maintenance by the Food and Drug Administration. The asthma treatment is a once-daily dose of two 1.25-microgram puffs.